Literature DB >> 3036813

A monoclonal antibody that inhibits cyclic AMP binding by the Escherichia coli cyclic AMP receptor protein.

X M Li, J S Krakow.   

Abstract

The monoclonal antibody (mAb) 64D1 was found to inhibit cAMP binding by the cAMP receptor protein (CRP) from Escherichia coli (Li, X.-M., and Krakow, J. S. (1985) J. Biol. Chem. 260, 4378-4383). CRP is relatively resistant to attack by the Staphylococcus aureus V8 protease, chymotrypsin, trypsin, and subtilisin whereas both mAb 64D1-CRP and cAMP-CRP are attacked by these proteases yielding N-terminal core fragments. The fragment patterns resulting from proteolysis of mAb 64D1-CRP and cAMP-CRP differ indicating that the CRP in each complex is in a different conformation. The data presented indicate that the preferred conformation of the antigenic site for mAb 64D1 is present in unliganded CRP. Binding of mAb 64D1 to CRP is inhibited at high cAMP concentration. Formation of a stable cAMP-CRP-lac P+-RNA polymerase open promoter complex resistant to dissociation by mAb 64D1 occurs at a much lower cAMP concentration. The observed increase in resistance to mAb 64D1 may reflect a possible conformational change in CRP effected by contact with RNA polymerase in the open promoter complex.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3036813

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  3 in total

Review 1.  Catabolite gene activator protein activation of lac transcription.

Authors:  W S Reznikoff
Journal:  J Bacteriol       Date:  1992-02       Impact factor: 3.490

2.  Characterization of the CRPCY core formed after treatment with carboxypeptidase Y.

Authors:  Z H Yang; S Bobin; J S Krakow
Journal:  Nucleic Acids Res       Date:  1991-08-11       Impact factor: 16.971

3.  Characterization of the binding of cAMP and cGMP to the CRP*598 mutant of the E. coli cAMP receptor protein.

Authors:  Y L Ren; S Garges; S Adhya; J S Krakow
Journal:  Nucleic Acids Res       Date:  1990-09-11       Impact factor: 16.971

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.